VIDAS® NEPHROCLEAR CCL14 Reference Interval Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- BioMérieux
- Enrollment
- 585
- Locations
- 2
- Primary Endpoint
- CCL14 concentration in urine
Study Overview
Brief Summary
This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEAR™ CCL14 test.
Detailed Description
The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in conjunction with clinical evaluation, in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI), as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment.
The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in patients 21 years of age or older.
The objective of this study is to determine the reference range for CCL14 concentration in Apparently Healthy Adults and Adults with Chronic, Stable Morbidities
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Apparently healthy adults (age ≥ 21 years);
- •Provide written informed consent for study (AST-017) participation
Exclusion Criteria
- •Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days;
- •Any known or suspected significant new onset or chronic morbid medical condition such as:
- •Active cancer
- •Arrhythmia (atrial fibrillation, heart block, ventricular tachycardia)
- •Chronic coagulation abnormality
- •Chronic obstructive pulmonary disease (including emphysema, chronic bronchitis, and asthma)
- •Chronic pancreatitis
- •Chronic renal insufficiency
- •Congestive heart failure
- •Coronary artery disease
- •Diabetes mellitus (Type 1 or Type 2)
- •Hyper- or hypothyroidism
- •Hyperlipidemia (includes hypercholesterolemia)
- •Hypertension
- •Immunocompromised
- •Inflammatory bowel disease (including Crohn's disease and ulcerative colitis)
- •Liver cirrhosis
- •Neuromuscular disease
- •Peripheral vascular disease (a.k.a. peripheral artery disease)
- •Polycystic kidney disease
- •Rheumatoid arthritis
- •Systemic Lupus Erythematosus
- •Trauma-related surgery within the last 6 months;
- •Any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous 3 months;
- •Received any blood product transfusion within the previous 2 months;
- •Pregnant women or children;
- •Prisoners or institutionalized individuals;
- •Already provided a urine sample for the AST-017 study
- •Inclusion Criteria:
- •Adults (age ≥ 21 years);
- •One or more of the following chronic, stable morbid conditions:
- •Active cancer
- •Arrhythmia (atrial fibrillation, heart block, ventricular tachycardia)
- •Chronic coagulation abnormality
- •Chronic obstructive pulmonary disease (including emphysema, chronic bronchitis, and asthma)
- •Chronic pancreatitis
- •Chronic renal insufficiency
- •Congestive heart failure
- •Coronary artery disease
- •Diabetes mellitus (Type 1 or Type 2)
- •Hyper- or hypothyroidism
- •Hyperlipidemia (includes hypercholesterolemia)
- •Hypertension
- •Immunocompromised
- •Inflammatory bowel disease (including Crohn's disease and ulcerative colitis)
- •Liver cirrhosis
- •Neuromuscular disease
- •Peripheral vascular disease (a.k.a. peripheral artery disease)
- •Polycystic kidney disease
- •Rheumatoid arthritis
- +15 more not shown
Outcomes
Primary Outcomes
CCL14 concentration in urine
Time Frame: Samples tested within 2 years of collection
CCL14 concentration will be measured using the VIDAS Necphroclear CCL14 Assay
Secondary Outcomes
No secondary outcomes reported